Next Generation Clinical Trial Transparency: Providing Management and Analysis of RNA Sequencing Data
LabKey has begun work with long-time partner the Immune Tolerance Network (ITN) to further clinical trial transparency by extending the LabKey Server platform to support management of RNA sequencing (RNA-Seq) and Next Gen Sequencing data. The ITN will be providing access to sequencing data, connecting raw data to downstream sequence analysis and visualizations that incorporate clinical data and other assay data through ITN’s research web portal, ITN TrialShare.
ITN TrialShare is an application built on the LabKey Server platform that supports both operational data management and post-publication sharing of data from clinical trials. ITN TrialShare was the first application of its kind to allow direct linking from major clinical trial publications to de-identified participant-level data and analyses.
As part of this new project, the LabKey team will provide custom development and configuration services to extend ITN TrialShare to support integration of and enhanced access to sequencing data. Improvements being explored as part of this project include:
- Support for big data downloads such as FAST-Q and BAM raw data files
- Integration with sequencing data transfer tools such as Globus Genomics
- The addition of assay data filtering for RNA-Seq data, T-cell Repertoire, and WGS data
- Support for Shiny in LabKey’s reporting framework, allowing real-time visualization of big data
About the Immune Tolerance Network
The Immune Tolerance Network (ITN) is a collaborative network for clinical research focused on the development of therapeutic approaches for asthma and allergy, autoimmune diseases, type 1 diabetes and solid organ transplantation that lead to immune tolerance. The ITN encompasses over 250 clinical sites and investigators and 14 core labs supporting 95 clinical trials (23 Allergy trials; 43 Autoimmunity trials; 29 Transplant trials). Read about LabKey and ITN’s partnership to develop ITN TrialShare >